DHX35 divergent transcript (DHX35-DT)

There is no evidence in the provided literature or widely used biological databases that "DHX35 divergent transcript" (DHX35-DT) is a recognized or characterized gene, protein, or therapeutic target. The documented molecule is "DHX35," which stands for "DEAH (Asp-Glu-Ala-His) box polypeptide 35," an RNA helicase belonging to the DExD/H-box helicase family. DHX35 is involved in the innate immune response, acting as a co-sensor for RIG-I and modulating antiviral immunity in human airway epithelial cells[1][2][3]. There are no references to a "divergent transcript" for DHX35 in the search results, nor does "DHX35-DT" appear as an established abbreviation, alias, or alternative name for a characterized molecular entity.\n\nAdditional context:\n- The canonical and functionally relevant target described in the current literature is "DEAH (Asp-Glu-Ala-His) box polypeptide 35" (DHX35).\n- "Divergent transcript" typically refers to non-coding RNAs that arise in a direction opposite to a canonical transcript at a given genomic locus, but there is no specific functional or pharmacological profile for "DHX35-DT."\n- If more details about "DHX35-DT" emerge in genomic databases or publications, structured information would require direct evidence of molecular identity, function, and classification, which are not present in current authoritative sources.